Sökning: WFRF:(Ekberg Karin) > Late effects in pat...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05700naa a2200457 4500 | |
001 | oai:DiVA.org:uu-500584 | |
003 | SwePub | |
008 | 230421s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:152320669 | |
009 | oai:lup.lub.lu.se:89e942d4-c623-4d6e-b305-cb4b502320dd | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5005842 URI |
024 | 7 | a https://doi.org/10.1182/bloodadvances.20220072412 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1523206692 URI |
024 | 7 | a https://lup.lub.lu.se/record/89e942d4-c623-4d6e-b305-cb4b502320dd2 URI |
040 | a (SwePub)uud (SwePub)kid (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Ekberg, Sarau Karolinska Institute,Karolinska Institutet,Uppsala universitet,Cancerprecisionsmedicin,Uppsala Akad Hosp, Uppsala, Sweden.;Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.,Uppsala University Hospital4 aut0 (Swepub:uu)sarek249 |
245 | 1 0 | a Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation |
264 | c 2023-03-14 | |
264 | 1 | b Elsevier,c 2023 |
338 | a electronic2 rdacarrier | |
520 | a Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. However, knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all patients with MCL, recorded in the Swedish Lymphoma Register, aged 18 to 69 years, diagnosed between 2000 and 2014 (N = 620; treated with HD-ASCT, n = 247) and 1:10 matched healthy comparators. Patients and comparators were followed up via the National Patient Register and Cause of Death Register, from 12 months after diagnosis or matching to December 2017. Incidence rate ratios of the numbers of outpatient visits, hospitalizations, and bed days were estimated using negative binomial regression models. In relation to the matched comparators, the rate of specialist and hospital visits was significantly higher among patients with MCL. Patients with MCL had especially high relative risks of infectious, respiratory, and blood disorders. Within this observation period, no difference in the rate of these complications, including secondary neoplasms, was observed between patients treated with and without HD-ASCT. Most of the patients died from their lymphoma and not from another cause or treatment complication. Taken together, our results imply that most of the posttreatment health care needs are related to the lymphoma disease itself, thus, indicating the need for more efficient treatment options. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Smedby, Karin E.u Karolinska Institute,Karolinska Institutet,Karolinska University Hospital4 aut |
700 | 1 | a Albertsson-Lindblad, Alexandrau Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)med-aab |
700 | 1 | a Jerkeman, Matsu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund,Skåne University Hospital4 aut0 (Swepub:lu)onk-mje |
700 | 1 | a Weibull, Caroline E.u Karolinska Institute,Karolinska Institutet4 aut |
700 | 1 | a Glimelius, Ingrid,d 1975-u Karolinska Institute,Karolinska Institutet,Uppsala universitet,Cancerprecisionsmedicin,Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.;Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Div Oncol, Lund, Sweden.,Uppsala University Hospital4 aut0 (Swepub:uu)inggl846 |
710 | 2 | a Uppsala universitetb Cancerprecisionsmedicin4 org |
773 | 0 | t Blood Advancesd : Elsevierg 7:5, s. 866-874q 7:5<866-874x 2473-9529x 2473-9537 |
856 | 4 | u https://doi.org/10.1182/bloodadvances.2022007241y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1752409/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1182/bloodadvances.2022007241x freey FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-500584 |
856 | 4 8 | u https://doi.org/10.1182/bloodadvances.2022007241 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:152320669 |
856 | 4 8 | u https://lup.lub.lu.se/record/89e942d4-c623-4d6e-b305-cb4b502320dd |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy